(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Researchers identified several antibodies to the nucleocapsid protein from a convalescent COVID-19 patient. Tests found some can inhibit complement hyperactivation and could potentially lead to new ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Q32 Bio Inc (NASDAQ:QTTB) saw its stock skyrocket 94% in premarket trading on Monday after revealing that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (NASDAQ:AKBA).

Complement is an ancient defense mechanism that evolved into a large protein-interaction network in mammals that initiates and serves innate immune functions and links innate immunity with adaptive ...

Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...